Hoth Therapeutics Announces Safety Results From AD001 Cohort 1 Of Phase 1b Clinical Trial Of BioLexa For Treatment Of Atopic Dermatitis; Interim Data Indicates BioLexa Was Well Tolerated With No Serious Adverse Effects